secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001437749-26-015018
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

UroGen Q1 2026: ZUSDURI revenue $29.2M (+109% QoQ); net loss narrows to $0.47/share
--------------------------------------------------------------------------------

- Total revenue $51.0M, up 152% YoY on ZUSDURI launch and JELMYTO growth.
- ZUSDURI net revenue $29.2M, 109% sequential growth; 256 unique prescribers as of March 31.
- JELMYTO revenue $21.7M (+7% YoY); FY 2026 guidance reaffirmed at $97–101M.
- Net loss $23.6M ($0.47/share) vs $43.8M ($0.92/share) in Q1 2025; cash $140.3M.
- UGN-103 NDA submission on track for H2 2026; six-month durability data expected mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000143774926015018/0001437749-26-015018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000143774926015018/urgn20260504_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-015018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer